Lipid-based nanoparticle-mediated combination therapy for breast cancer management: a comprehensive review

[1]  C. Len,et al.  Monoclonal antibodies in breast cancer: a critical appraisal. , 2023, Critical reviews in oncology/hematology.

[2]  Xiaoqing Yi,et al.  Stepwise responsive carboxymethyl chitosan-based nanoplatform for effective drug-resistant breast cancer suppression. , 2022, Carbohydrate polymers.

[3]  S. Beg,et al.  Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies , 2022, Pharmaceutics.

[4]  K. Kohli,et al.  Combinatorial chemosensitive Nanomedicine approach for the treatment of Breast cancer. , 2022, Current molecular medicine.

[5]  Mahfoozur Rahman,et al.  Biocompatible Polymeric Nanoparticles for Effective Codelivery of Tamoxifen with Ganoderic Acid A: Systematic Approach for Improved Breast Cancer Therapeutics , 2022, Journal of Cluster Science.

[6]  V. Torchilin,et al.  Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers , 2022, Pharmaceutics.

[7]  S. Baboota,et al.  Solid Self-Nano Emulsifying Nanoplatform Loaded with Tamoxifen and Resveratrol for Treatment of Breast Cancer , 2022, Pharmaceutics.

[8]  Omer Aydin,et al.  Co-delivery of Bcl-2 siRNA and doxorubicin through gold nanoparticle-based delivery system for a combined cancer therapy approach , 2022, Journal of Drug Delivery Science and Technology.

[9]  N. Zarghami,et al.  The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action , 2022, Applied Biochemistry and Biotechnology.

[10]  Hongmei Liu,et al.  A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer , 2022, Nano Research.

[11]  V. rani,et al.  New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy , 2022, Current research in pharmacology and drug discovery.

[12]  Sherine N. Khattab,et al.  Methotrexate-Lactoferrin Targeted Exemestane Cubosomes for Synergistic Breast Cancer Therapy , 2022, Frontiers in Chemistry.

[13]  Xiaoling Fu,et al.  Combinational Chemoimmunotherapy for Breast Cancer by Codelivery of Doxorubicin and PD-L1 siRNA Using a PAMAM-Incorporated Liposomal Nanoplatform. , 2022, ACS applied materials & interfaces.

[14]  J. Varshosaz,et al.  Co-delivery of STAT3 siRNA and methotrexate in breast cancer cells , 2022, Artificial cells, nanomedicine, and biotechnology.

[15]  A. Asoodeh,et al.  Fabrication, characterization and in vitro cell exposure study of zein-chitosan nanoparticles for co-delivery of curcumin and berberine. , 2022, International journal of biological macromolecules.

[16]  Wei Liu,et al.  Co-Delivery of Repurposing Itraconazole and VEGF siRNA by Composite Nanoparticulate System for Collaborative Anti-Angiogenesis and Anti-Tumor Efficacy against Breast Cancer , 2022, Pharmaceutics.

[17]  K. Kohli,et al.  Recent advances in targeted nanotherapeutic approaches for breast cancer management. , 2021, Nanomedicine.

[18]  Hossein Roghani-Shahraki,et al.  The Therapeutic Potential of Common Herbal and Nano-Based Herbal Formulations against Ovarian Cancer: New Insight into the Current Evidence , 2021, Pharmaceuticals.

[19]  Guobin Wang,et al.  Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA. , 2021, Acta biomaterialia.

[20]  S. Qusti,et al.  Impacting the Remedial Potential of Nano Delivery-Based Flavonoids for Breast Cancer Treatment , 2021, Molecules.

[21]  R. Salehi,et al.  Co-delivery of doxorubicin and conferone by novel pH-responsive β-cyclodextrin grafted micelles triggers apoptosis of metastatic human breast cancer cells , 2021, Scientific Reports.

[22]  N. Sheibani,et al.  Silencing of HMGA2 by siRNA Loaded Methotrexate Functionalized Polyamidoamine Dendrimer for Human Breast Cancer Cell Therapy , 2021, Genes.

[23]  W. Mamdouh,et al.  Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies. , 2021, International journal of biological macromolecules.

[24]  Ke Zhang,et al.  Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways , 2021, Frontiers in Oncology.

[25]  K. Dhama,et al.  Curcumin and its different forms: A review on fish nutrition , 2021 .

[26]  M. Shokrgozar,et al.  Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin siRNA Using Polyethylenimine Modified Silk Fibroin Nanoparticles. , 2021, ACS biomaterials science & engineering.

[27]  H. Bardania,et al.  Intercalation of curcumin into liposomal chemotherapeutic agent augments apoptosis in breast cancer cells , 2020, Journal of biomaterials applications.

[28]  A. Bahreyni,et al.  Emerging nanomedicines for effective breast cancer immunotherapy , 2020, Journal of Nanobiotechnology.

[29]  Han Jiang,et al.  Therapeutic effect of curcumin on oral diseases: A literature review , 2020, Phytotherapy research : PTR.

[30]  F. Mottaghy,et al.  HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  R. Mohammadinejad,et al.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy , 2020, ACS combinatorial science.

[32]  Hana M. Gashlan,et al.  Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells , 2020, Scientific Reports.

[33]  Biqiong Wang,et al.  Co-delivery of Paclitaxel and Curcumin by Biodegradable Polymeric Nanoparticles for Breast Cancer Chemotherapy. , 2020, International journal of pharmaceutics.

[34]  G. Zhai,et al.  Paclitaxel and quercetin co-loaded functional mesoporous silica nanoparticles overcoming multidrug resistance in breast cancer. , 2020, Colloids and surfaces. B, Biointerfaces.

[35]  D. P. Sarkar,et al.  Natural products and polymeric nanocarriers for cancer treatment: a review , 2020, Environmental Chemistry Letters.

[36]  L. Weiner,et al.  Monoclonal Antibodies in Cancer Therapy , 2020, Antibodies.

[37]  Akshay Jain,et al.  Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer , 2020, Science Advances.

[38]  Bin Liu,et al.  nnnnnnnnSequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition. , 2020, Acta biomaterialia.

[39]  Seyedeh Sara Esnaashari,et al.  A Combinational Approach Towards Treatment of Breast Cancer: an Analysis of Noscapine-Loaded Polymeric Nanoparticles and Doxorubicin , 2020, AAPS PharmSciTech.

[40]  M. Shakibaei,et al.  Flavonoids in Cancer Metastasis , 2020, Cancers.

[41]  Yongzhuo Huang,et al.  Combination therapy based on nano codelivery for overcoming cancer drug resistance , 2020 .

[42]  H. Khan,et al.  Therapeutic potentials of curcumin in the treatment of non‐small‐cell lung carcinoma , 2020, Phytotherapy research : PTR.

[43]  B. Czerniecki,et al.  Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond , 2020, npj Breast Cancer.

[44]  Y. Ghasemi,et al.  Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells , 2020, Cell & Bioscience.

[45]  Yunmei Song,et al.  Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles , 2020, Molecules.

[46]  Xiaofang Wang,et al.  Identification and biological evaluation of natural product Biochanin A. , 2020, Bioorganic chemistry.

[47]  P. Kubatka,et al.  Therapeutic Potential of Plant Phenolic Acids in the Treatment of Cancer , 2020, Biomolecules.

[48]  M. Montazeri,et al.  Synergistic anticancer effects of electrospun nanofiber-mediated codelivery of Curcumin and Chrysin: Possible application in prevention of breast cancer local recurrence , 2020 .

[49]  Meng Wang,et al.  Preparation and Characterization of PLGA–PEG–PLGA Nanoparticles Containing Salidroside and Tamoxifen for Breast Cancer Therapy , 2020, AAPS PharmSciTech.

[50]  S. Samuel,et al.  Anti-Angiogenic Effects of Phytochemicals on miRNA Regulating Breast Cancer Progression , 2020, Biomolecules.

[51]  S. Akhter,et al.  Co-encapsulation of Docetaxel and Thymoquinone in mPEG-DSPE-Vitamin E TPGS-Lipid nanocapsules for breast cancer therapy: Formulation Optimization and Implications on cellular and in vivo toxicity. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[52]  Min Wu,et al.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects , 2020, Signal Transduction and Targeted Therapy.

[53]  A. Hosseini,et al.  Quercetin: A promising phytochemical for the treatment of glioblastoma multiforme , 2019, BioFactors.

[54]  A. Amini,et al.  Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation. , 2019, Colloids and surfaces. B, Biointerfaces.

[55]  N. Kaur,et al.  Polymeric Core–Shell Combinatorial Nanomedicine for Synergistic Anticancer Therapy , 2019, ACS Omega.

[56]  Sajjad Karim,et al.  Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. , 2019, Seminars in cancer biology.

[57]  K. Kohli,et al.  Tamoxifen and Sulphoraphane for the breast cancer management: A synergistic nanomedicine approach. , 2019, Medical hypotheses.

[58]  Upendra Bulbake,et al.  Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer. , 2019, Chemistry and physics of lipids.

[59]  F. Ahmad,et al.  Improved chemotherapeutic efficacy against resistant human breast cancer cells with co-delivery of Docetaxel and Thymoquinone by Chitosan grafted lipid nanocapsules: Formulation optimization, in vitro and in vivo studies. , 2019, Colloids and surfaces. B, Biointerfaces.

[60]  A. Avan,et al.  Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells. , 2019, Pathology, research and practice.

[61]  M. Khazaei,et al.  Active targeting carrier for breast cancer treatment: Monoclonal antibody conjugated epirubicin loaded nanoparticle , 2019, Journal of Drug Delivery Science and Technology.

[62]  Xiyun Deng,et al.  Synergistically Enhanced Inhibitory Effects of Pullulan Nanoparticle-Mediated Co-Delivery of Lovastatin and Doxorubicin to Triple-Negative Breast Cancer Cells , 2019, Nanoscale Research Letters.

[63]  F. Fisusi,et al.  Drug Combinations in Breast Cancer Therapy , 2019, Pharmaceutical nanotechnology.

[64]  Jeong-Sook Park,et al.  Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment , 2019, Journal of Pharmaceutical Investigation.

[65]  R. Pushpalatha,et al.  Cyclodextrin nanosponge based hydrogel for the transdermal co-delivery of curcumin and resveratrol: Development, optimization, in vitro and ex vivo evaluation , 2019, Journal of Drug Delivery Science and Technology.

[66]  J. Das,et al.  Targeted delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy. , 2019, Materials science & engineering. C, Materials for biological applications.

[67]  Catalina Carrasco-Pozo,et al.  The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism , 2019, International journal of molecular sciences.

[68]  Z. Asemi,et al.  Quercetin: a natural compound for ovarian cancer treatment , 2019, Journal of Ovarian Research.

[69]  Kinam Park.  The beginning of the end of the nanomedicine hype. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[70]  P. Saw,et al.  siRNA therapeutics: a clinical reality , 2019, Science China Life Sciences.

[71]  Sajini D Hettiarachchi,et al.  Nanoparticle-mediated targeted drug delivery for breast cancer treatment. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[72]  Lin-Fang Du,et al.  In Silico Investigation of the Anti-Tumor Mechanisms of Epigallocatechin-3-Gallate , 2019, Molecules.

[73]  Xing-jie Liang,et al.  Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail. , 2019, ACS nano.

[74]  L. Du,et al.  Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. , 2019, Acta biomaterialia.

[75]  Dexin Yin,et al.  Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway , 2018, BMC Cancer.

[76]  S. Gurunathan,et al.  Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer , 2018, International journal of molecular sciences.

[77]  A. Jose,et al.  Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment , 2018, Journal of liposome research.

[78]  V. Thiéry,et al.  Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms. , 2018, Fitoterapia.

[79]  A. Rauf,et al.  Anticancer potential of quercetin: A comprehensive review , 2018, Phytotherapy research : PTR.

[80]  N. Zarghami,et al.  Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells , 2018, Artificial cells, nanomedicine, and biotechnology.

[81]  Medhat A. Haroun,et al.  Self‐assembled amphiphilic zein‐lactoferrin micelles for tumor targeted co‐delivery of rapamycin and wogonin to breast cancer , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[82]  Sanyog Jain,et al.  Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[83]  Shailesh Singh,et al.  Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways , 2018, World Journal of Surgical Oncology.

[84]  C. Dora,et al.  Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management. , 2018, Acta biomaterialia.

[85]  S. Nakano,et al.  In Vitro and In Silico Studies of the Molecular Interactions of Epigallocatechin-3-O-gallate (EGCG) with Proteins That Explain the Health Benefits of Green Tea , 2018, Molecules.

[86]  T. Tsai,et al.  Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics , 2018, Journal of food and drug analysis.

[87]  J. Zou,et al.  Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression , 2018, Oncotarget.

[88]  Esraa M. Mosalam,et al.  Enhanced anticancer effect and reduced toxicity of doxorubicin in combination with thymoquinone released from poly‐N‐acetyl glucosamine nanomatrix in mice bearing solid Ehrlish carcinoma , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[89]  M. Helmy,et al.  Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy. , 2017, Nanomedicine.

[90]  Guimei Lin,et al.  Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. , 2017, Acta biomaterialia.

[91]  Yue Liu,et al.  Effects of quercetin on proliferation and migration of human glioblastoma U251 cells. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[92]  Yaping Li,et al.  Co-delivery of docetaxel and silibinin using pH-sensitive micelles improves therapy of metastatic breast cancer , 2017, Acta Pharmacologica Sinica.

[93]  Premjeet Singh Sandhu,et al.  Natural lipids enriched self-nano-emulsifying systems for effective co-delivery of tamoxifen and naringenin: Systematic approach for improved breast cancer therapeutics. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[94]  S. Sheweita,et al.  Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy , 2017, Pharmaceutical Research.

[95]  C. Gross,et al.  Use of Alternative Medicine for Cancer and Its Impact on Survival. , 2017, Journal of the National Cancer Institute.

[96]  Y. Luan,et al.  Co-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancer. , 2017, Colloids and surfaces. B, Biointerfaces.

[97]  Hong Sun,et al.  Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. , 2017, Oncology reports.

[98]  P. Vogt,et al.  Anti-apoptotic protein Lifeguard does not act as a tumor marker in breast cancer , 2017, Oncology letters.

[99]  D. Merlin,et al.  Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy , 2017, Expert opinion on drug delivery.

[100]  Rui Xue Zhang,et al.  Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[101]  E. Williamson,et al.  An assessment of the impact of herb-drug combinations used by cancer patients , 2016, BMC Complementary and Alternative Medicine.

[102]  Wahid Khan,et al.  Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment , 2016, Drug delivery.

[103]  A. Bishayee,et al.  Molecular Targets Underlying the Anticancer Effects of Quercetin: An Update , 2016, Nutrients.

[104]  Junyan Wu,et al.  Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer. , 2016, Journal of biomedical nanotechnology.

[105]  Qian Liu,et al.  Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy , 2016, Drug delivery.

[106]  D. Kohane,et al.  Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy. , 2016, Acta biomaterialia.

[107]  Zhen Gu,et al.  Recent advances of cocktail chemotherapy by combination drug delivery systems. , 2016, Advanced drug delivery reviews.

[108]  M. Kester,et al.  Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[109]  Xiaoyuan Chen,et al.  A nanoparticulate pre-chemosensitizer for efficacious chemotherapy of multidrug resistant breast cancer , 2016, Scientific Reports.

[110]  U. Mony,et al.  Sequential release of epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[111]  R. Weichselbaum,et al.  Nanomedicine for Combination Therapy of Cancer , 2015, EBioMedicine.

[112]  Xiaoyang Xu,et al.  Cancer Nanomedicine: From Targeted Delivery to Combination Therapy , 2015, Trends in molecular medicine.

[113]  M. Cooper,et al.  Natural product and natural product derived drugs in clinical trials. , 2014, Natural product reports.

[114]  R. Wu,et al.  Curcumin Modulates miR‐19/PTEN/AKT/p53 Axis to Suppress Bisphenol A‐induced MCF‐7 Breast Cancer Cell Proliferation , 2014, Phytotherapy research : PTR.

[115]  R. Bristow,et al.  Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. , 2014, Molecular pharmaceutics.

[116]  Manish Kohli,et al.  Nanoparticles for combination drug therapy. , 2013, ACS nano.

[117]  Paula T Hammond,et al.  Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. , 2013, ACS nano.

[118]  J. Cusack,et al.  Targeting the NF-κB pathway in cancer therapy. , 2013, Surgical oncology clinics of North America.

[119]  M. Kaplan,et al.  Potential benefits of green tea polyphenol EGCG in the prevention and treatment of vascular inflammation in rheumatoid arthritis. , 2013, Life sciences.

[120]  T. T. Maliekal,et al.  Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance. , 2013, Antioxidants & redox signaling.

[121]  K. Dao,et al.  Targeting the estrogen receptor using steroid-therapeutic drug conjugates (hybrids). , 2012, Bioconjugate chemistry.

[122]  Robert Langer,et al.  Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. , 2012, Nanomedicine.

[123]  Chandana Mohanty,et al.  Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. , 2012, Drug discovery today.

[124]  R. Deberardinis,et al.  Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. , 2012, Cell metabolism.

[125]  Thomas Efferth,et al.  P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. , 2012, Journal of ethnopharmacology.

[126]  Liangfang Zhang,et al.  Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. , 2012, Biochemical pharmacology.

[127]  R. Pestell,et al.  Breast cancer stem cells. , 2012, The international journal of biochemistry & cell biology.

[128]  David J Newman,et al.  Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.

[129]  S. Shankar,et al.  Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. , 2011, Biochemical pharmacology.

[130]  Afsaneh Lavasanifar,et al.  Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. , 2011, ACS nano.

[131]  P. Vogt,et al.  Silencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumor cell lines MCF-7 and SW872 to perifosine-induced cell death activation. , 2011, Oncology letters.

[132]  I. Holen,et al.  Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies , 2011, International journal of breast cancer.

[133]  Kam W Leong,et al.  Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. , 2011, ACS nano.

[134]  James H. Adair,et al.  Nanoparticulate alternatives for drug delivery. , 2010, ACS nano.

[135]  L. Klotz,et al.  Epigallocatechin gallate-induced modulation of FoxO signaling in mammalian cells and C. elegans: FoxO stimulation is masked via PI3K/Akt activation by hydrogen peroxide formed in cell culture. , 2010, Archives of biochemistry and biophysics.

[136]  Taryn R. Bagby,et al.  Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[137]  P. Vogt,et al.  Transactivation of lifeguard (LFG) by Akt-/LEF-1 pathway in MCF-7 and MDA-MB 231 human breast cancer cells , 2010, Apoptosis.

[138]  P. Vogt,et al.  The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues , 2010, Cellular & Molecular Biology Letters.

[139]  Liangfang Zhang,et al.  Therapeutic nanoparticles to combat cancer drug resistance. , 2009, Current drug metabolism.

[140]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[141]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[142]  A. Mukherjee,et al.  Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. , 2009, Anti-cancer agents in medicinal chemistry.

[143]  D. Linseman,et al.  Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. , 2009, Antioxidants & redox signaling.

[144]  A. Bast,et al.  Health effects of quercetin: from antioxidant to nutraceutical. , 2008, European journal of pharmacology.

[145]  Qun Zhou,et al.  Antiestrogenic effect of 20S‐protopanaxadiol and its synergy with tamoxifen on breast cancer cells , 2007, Cancer.

[146]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[147]  Vladimir P. Torchilin,et al.  Nanoparticulates as Drug Carriers , 2006 .

[148]  L. Mayer,et al.  Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. , 2006, Oncology research.

[149]  B. Trock,et al.  Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. , 2005, Seminars in oncology.

[150]  Chintamani,et al.  Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study , 2005, World journal of surgical oncology.

[151]  M. Butler.  Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.

[152]  R. Srivastava,et al.  Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signaling and apoptotic pathways in A375 cells. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[153]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[154]  Ming-Tsan Lin,et al.  Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies. , 2018, The Journal of nutritional biochemistry.

[155]  S. Sivasubramanian,et al.  Paclitaxel/epigallocatechin gallate coloaded liposome: a synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells. , 2015, Colloids and surfaces. B, Biointerfaces.

[156]  Lawrence Mayer,et al.  In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.

[157]  J. Manias,et al.  A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells , 2008, Breast Cancer Research and Treatment.